Fresenius stock gains as mAbxience takeover reaches full control

Published on 10/30/2026 at 15:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock gains as the healthcare group takes full control of mAbxience. The deal strengthens its biosimilars platform ahead of third-quarter results.

Full ownership raises execution stakes

Fresenius Kabi now controls mAbxience from development and manufacturing through commercialization.
Fresenius is scheduled to release third-quarter results on November 4, 2026.

Fresenius, DE000FRE5EN2, Illustration mit AI erstellt.

Fresenius has completed its takeover of the remaining stake in mAbxience, giving Fresenius Kabi full control of the biosimilars platform. The transaction was completed on September 30, 2026, and mAbxience announced the structure on October 1.

In its press release, mAbxience said Fresenius acquired the remaining 45 percent from Insud Pharma. The consideration totals up to 750 million euros, including a contingent payment linked to site approvals.

Control across the biosimilars chain

Full ownership brings development, manufacturing and commercialization under Fresenius Kabi's Biopharma business. mAbxience said the structure should improve control over costs, production capacity and launch timing while supporting supply resilience and future innovation.

The Spanish-based business has four approved products, a pipeline in development and operations spanning Europe and South America. It also serves customers in more than 100 markets and has a network of more than 40 partners, according to the company.

Fresenius stock traded at 47.77 euros on Lang & Schwarz at 4:36 p.m. CEST on Friday, October 30, 2026, 1.64 percent above the Xetra close of Thursday, October 29. The real-time quote of Fresenius stock remains available for investors.